OncologyPRO: The home of ESMO’s educational and scientific resources

From ASCO 2022 Annual Meeting:
Preliminary findings indicate that patients with tumours harbouring NRG1 fusions may benefit from treatment with zenocutuzumab or seribantumab

From ASCO 2022 Annual Meeting:
Phase II results suggest trastuzumab deruxtecan may offer a novel treatment option for patients with HER2-expressing advanced biliary tract cancer

From ASCO 2022 Annual Meeting:
Combining first-line triplet therapy and lenalidomide maintenance with autologous stem-cell transplantation significantly improves multiple myeloma progression-free survival

From ASCO 2022 Annual Meeting:
Ifosfamide achieved better survival outcomes than topotecan plus cyclophosphamide among rEECur trial participants with recurrent or primary refractory Ewing sarcoma

From ASCO 2022 Annual Meeting:
Amivantamab shows activity in NSCLC patients with a primary MET exon 14 skipping mutation and when used in combination with lazertinib for those with EGFR mutations who have progressed after osimertinib and chemotherapy

From ESMO Breast Cancer 2022:
For patients with hormone receptor-positive, HER2-negative advanced breast cancer, the addition of ribociclib to fulvestrant continues to significantly improves overall survival after more than 70 months

From ESMO Breast Cancer 2022:
Preliminary phase Ib/II trial results suggest that first-line treatment with datopotamab deruxtecan plus durvalumab is active against locally advanced and metastatic triple-negative breast cancer

From ESMO Breast Cancer 2022:
Trastuzumab deruxtecan may help control intracranial metastases in patients with HER2-positive breast cancer